

Equity Research

November 12, 2014

Price: \$19.43 (11/11/2014)

Price Target: \$45.00

OUTPERFORM (1)

Phil Nadeau, Ph.D.

646.562.1336

phil.nadeau@cowen.com

Key Data

| | |
|------------------------|-----------------|
| Symbol | NASDAQ: ZFGN |
| 52-Week Range: | \$21.96 - 16.01 |
| Market Cap (MM): | \$441.2 |
| Net Debt (MM): | \$(6.8) |
| Cash/Share: | NA |
| Dil. Shares Out (MM): | 22.7 |
| Enterprise Value (MM): | \$314.4 |
| ROIC: | NA |
| ROE (LTM): | NA |
| BV/Share: | \$5.52 |
| Dividend: | NA |

| FY (Dec) | 2013A | 2014E | 2015E |
|---------------------------|----------|-----------|----------|
| Earnings Per Share | | | |
| Q1 | - | \$(0.98)A | \$(0.56) |
| Prior Q1 | - | - | - |
| Q2 | - | \$(2.96)A | \$(0.58) |
| Prior Q2 | - | - | - |
| Q3 | - | \$(0.65) | \$(0.62) |
| Prior Q3 | - | \$(0.86) | - |
| Q4 | - | \$(0.54) | \$(0.63) |
| Prior Q4 | - | \$(0.53) | - |
| Year | \$(3.11) | \$(2.89) | \$(2.40) |
| Prior Year | - | \$(3.25) | - |
| P/E | NM | NM | NM |
| Consensus EPS | - | \$(5.12) | \$(2.66) |

Consensus source: Thomson Reuters

Revenue (MM)

| | | | |
|------|-------|-------|-------|
| Year | \$0.0 | \$0.0 | \$0.0 |
|------|-------|-------|-------|

Earnings Update

Reports Q3; Gearing Up For An Eventful 2015

The Cowen Insight

Zafgen reported Q3 financials and updated pipeline progress. Data from a Ph. IIa of beloranib in craniopharyngioma-associated obesity is on track for Q1:15. A U.S. Ph. III trial of beloranib in Prader-Willi Syndrome (PWS) began in Q3 with initial data expected in Q4:15. We expect beloranib's progress to drive outperformance in ZFGN.

Q3 Financials: Funding Into H2:16 Through Multiple Milestones.

Zafgen reported a Q3 net loss of \$14.7MM and ended the quarter with \$127MM in cash. Zafgen expects to end 2014 with greater than \$100MM in cash and anticipates its current cash balance will fund operations into H2:16 through key pipeline milestones including results from beloranib's Phase III studies in PWS and Phase II trials in HIAO and severe obesity.

Beloranib's U.S. Phase III In PWS Initiated, EU Trial To Follow In H1:15.

The U.S. Phase III trial of beloranib in PWS, bestPWS, was initiated in October. bestPWS will enroll and randomize approximately 100 adolescents (>12 years of age) and adults with PWS to receive beloranib at 1.8 mg or 2.4 mg or placebo via sub-Q injections twice-weekly for six months. Primary endpoints will evaluate improvements in total body fat mass and hyperphagia-related behaviors. The trial will be considered positive if either endpoint is met with $p < 0.025$ or if both are met with $p < 0.05$. Zafgen anticipates that initial six-month data from the U.S. trial will be available by Q4:15. In H1:15 Zafgen expects to initiate an EU Phase III study with beloranib in PWS mirroring the design of the U.S. trial.

Data From Beloranib's Phase IIa In Hypothalamic Injury Associated Obesity (HIAO) On Track For Q1:15.

The 14-patient Phase IIa proof of concept trial in HIAO is on track to be completed by YE:14 with data available in Q1:15. Hypothalamic injury in the trial is defined as patients with craniopharyngioma, stroke, brain trauma, or radiation injuries to the hypothalamus. The primary endpoint will evaluate the change in body weight from baseline. Zafgen will consider proof-of-concept achieved should beloranib produce weight loss in the range of 3 to 4 kg over the 4 week study period or demonstrate statistically significant weight loss vs. placebo.

Beloranib's Phase IIb In Severe Obesity On Track To Begin By YE:14.

By YE:14 Zafgen plans to initiate a long-term Phase IIb study of beloranib in obesity. Prior Phase IIa data showed treatment with beloranib resulted in mean weight changes from baseline of 7 to 11 kg with favorable trends in CV parameters. Zafgen anticipates that preliminary six-month data will be available in Q4:15.

At A Glance

Our Investment Thesis

Zafgen's lead asset beloranib is in development for the treatment of hyperphagia (insatiable appetite) and obesity in Prader-Willi syndrome, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen has completed five clinical trials in over 200 subjects including obese volunteers and Prader-Willi Syndrome patients. In these trials beloranib has reduced fat mass and controlled hyperphagia while maintaining an acceptable tolerability and safety profile. Our consultants find the >50% decrease in hyperphagia produced in PWS patients particularly striking, as beloranib is the first agent shown to produce a reduction in food seeking behavior. Beloranib entered a Phase III trial in Prader-Willi syndrome October 14, with initial data possible in Q4:2015. Our DCF suggests that Zafgen is undervalued based on beloranib's potential in Prader-Willi and craniopharyngioma alone, with no contribution from other indications or pipeline programs.

Forthcoming Catalysts

- Initiate Phase IIb trial of beloranib in severe obesity, YE:14
- Initial data from Ph. IIa of beloranib in craniopharyngioma, Q1:15
- Initial data from U.S. Ph. III trial of beloranib in Prader-Willi, Q4:15

Base Case Assumptions

- Beloranib is successfully developed for Prader-Willi and craniopharyngioma, achieving \$1.0B in sales by 2026.
- Beloranib is not developed for any other indications.
- The rest of Zafgen's pipeline does not contribute significant value.

Upside Scenario

- Beloranib is successfully developed for Prader-Willi and craniopharyngioma, achieving >\$1.0B in sales by 2026.
- Beloranib is also successfully developed for other indications.
- ZGN-839 is successfully developed for NASH and/or type 2 diabetes
- Another pipeline candidate contributes significant value.

Downside Scenario

- Beloranib is not successfully developed for Prader-Willi and/or craniopharyngioma.
- Beloranib does not achieve \$1.0B in sales by 2026.
- The rest of Zafgen's pipeline does not contribute much value.

Price Performance



Source: Bloomberg

Company Description

Zafgen is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity. Zafgen's beloranib is a novel small molecule inhibitor of methionine aminopeptidase 2 (MetAP2). It is in Phase III trial in Prader-Willi syndrome with data expected during Q4:15. Zafgen will initiate a Phase IIb trial in general obesity by YE:14. A Phase IIa trial in craniopharyngioma-associated obesity is ongoing, with data expected during Q1:15. Prader-Willi syndrome and craniopharyngioma-associated obesity are orphan disorders that each afflict approximately 20K patients in the U.S. and EU. We estimate that beloranib could address a \$1.5B+ opportunity in these two conditions. Behind beloranib, Zafgen is developing an orally active MetAP2 inhibitor, ZGN-839. ZGN-839 has shown early efficacy in preclinical models of Nonalcoholic Steatohepatitis (NASH) and type 2 diabetes. Zafgen plans to submit an IND for ZGN-839 in H1:15.

Analyst Top Picks

| | Ticker | Price (11/11/2014) | Price Target | Rating |
|-------------------------|--------|--------------------|--------------|------------|
| BioMarin Pharmaceutical | BMRN | \$86.12 | \$95.00 | Outperform |
| Gilead Sciences | GILD | \$108.01 | \$125.00 | Outperform |
| Neurocrine Biosciences | NBIX | \$19.20 | \$20.00 | Outperform |

IND Filing For ZGN-839 On Track For H1:15.

Zafgen is developing an orally-active second-generation MetAP2 inhibitor, ZGN-839. ZGN-839 has shown early efficacy in preclinical models of Nonalcoholic Steatohepatitis (NASH) and type 2 diabetes. Zafgen is conducting PK and PD studies in preclinical models and is on track to submit an IND in H1:15.

Investment Thesis

Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Zafgen's lead asset, beloranib, is a novel small molecule inhibitor of methionine aminopeptidase 2 (MetAP2) that is in development for the treatment of hyperphagia (insatiable appetite) and obesity in Prader-Willi Syndrome, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen has completed five clinical trials in over 200 subjects including obese volunteers and Prader-Willi Syndrome patients. In these trials beloranib has reduced fat mass and controlled hyperphagia while maintaining an acceptable tolerability and safety profile. Our consultants find the >50% decrease in hyperphagia produced in Prader-Willi patients particularly striking, as beloranib is the first agent shown to produce a reduction in food seeking behaviors in these patients, a key area of unmet need. Beloranib entered a Phase III trial in Prader-Willi Syndrome in October 2014, with initial data possible in Q4:2015. By YE:14 Zafgen will initiate a Phase IIb trial in general obesity, with data possible in Q4:2015. A Phase IIa trial in craniopharyngioma-associated obesity is ongoing, with data expected during Q1:2015. Prader-Willi Syndrome and craniopharyngioma-associated obesity are orphan disorders that each afflict approximately 20K patients in the U.S. and EU. We estimate that beloranib could address a \$1.5B+ opportunity in these two conditions. Behind beloranib, Zafgen is developing an orally active second-generation MetAP2 inhibitor, ZGN-839. ZGN-839 has shown early efficacy in preclinical models of Nonalcoholic Steatohepatitis (NASH) and type 2 diabetes. Zafgen plans to submit an IND for ZGN-839 in H1:15. Our DCF analysis suggests that Zafgen is undervalued based on beloranib's potential in Prader-Willi and craniopharyngioma-associated obesity alone, with no contribution from other indications or pipeline programs. We maintain our Outperform rating and a \$45 price target.

Zafgen Upcoming Milestones

| Milestone | Timing |
|--|--------|
| Initiate Phase IIb trial of beloranib in severe obesity (ZAF-203) | YE:14 |
| Initial data from Phase IIa of beloranib in craniopharyngioma-associated obesity (ZAF-221) | Q1:15 |
| Initiate Phase III trial of beloranib in PWS in EU | H1:15 |
| File IND for ZGN-839 in type II diabetes, NASH and abdominal obesity | H1:15 |
| Interim 6-month Phase IIb data from beloranib in severe obesity (complete Phase IIb; development decision point) | Q4:15 |
| Phase III data from beloranib in PWS in U.S. (ZAF-311-bestPWS) | Q4:15 |
| Nomination of second-generation MetAP2i candidate | 2016 |

Source: Cowen and Company

Zafgen Quarterly P&L (\$MM)

| | Q1:14A | Q2:14A | Q3:14A | Q4:14E | 2014E | Q1:15E | Q2:15E | Q3:15E | Q4:15E | 2015E |
|--|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Boloranib | - | - | - | - | - | - | - | - | - | - |
| License/milestones revenue | - | - | - | - | - | - | - | - | - | - |
| Total Revenue | - | - | - | - | - | - | - | - | - | - |
| COGS | - | - | - | - | - | - | - | - | - | - |
| R&D | 3.3 | 4.7 | 12.1 | 10.2 | 30.2 | 10.5 | 11.0 | 11.5 | 11.5 | 44.5 |
| SG&A | 1.2 | 1.3 | 2.3 | 2.2 | 7.0 | 2.1 | 2.2 | 2.7 | 3.0 | 10.0 |
| Other | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 4.5 | 6.0 | 14.4 | 12.4 | 37.3 | 12.6 | 13.2 | 14.2 | 14.5 | 54.5 |
| Operating Income / (Loss) | (4.5) | (6.0) | (14.4) | (12.4) | (37.3) | (12.6) | (13.2) | (14.2) | (14.5) | (54.5) |
| Interest Income | - | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 |
| Interest Expenses | (0.0) | (0.4) | (0.2) | (0.0) | (0.7) | (0.4) | (0.4) | (0.4) | (0.4) | (1.6) |
| Foreign Currency Transaction Gains (Losses), n | 0.1 | 0.0 | (0.1) | - | (0.0) | - | - | - | - | - |
| Pretax net income | (4.5) | (6.4) | (14.7) | (12.3) | (37.9) | (12.9) | (13.5) | (14.5) | (14.8) | (55.7) |
| Accretion of redeemable convertible preferred st | (0.0) | (0.0) | - | - | - | - | - | - | - | - |
| Taxes | - | - | - | - | - | - | - | - | - | - |
| <i>Tax Rate</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> |
| GAAP Net Income | (4.5) | (6.4) | (14.7) | (12.3) | (37.9) | (12.9) | (13.5) | (14.5) | (14.8) | (55.7) |
| GAAP EPS | \$ (0.98) | \$ (2.96) | \$ (0.65) | \$ (0.54) | \$ (2.89) | \$ (0.56) | \$ (0.58) | \$ (0.62) | \$ (0.63) | \$ (2.40) |
| Diluted Shares Outstanding (MM) | 4.6 | 2.2 | 22.7 | 22.9 | 13.1 | 23.0 | 23.2 | 23.3 | 23.4 | 23.2 |

Source: Cowen and Company

Zafgen Annual P&L (\$MM)

| | 2013A | 2014E | 2015E | 2016E | 2017E | 2018E | 2019E | 2020E |
|--|------------------|------------------|------------------|------------------|------------------|------------------|----------------|----------------|
| Boleranib | - | - | - | - | 25.0 | 95.0 | 200.0 | 325.0 |
| License/milestones revenue | - | - | - | - | - | - | - | - |
| Total Revenue | - | - | - | - | 25.0 | 95.0 | 200.0 | 325.0 |
| COGS | - | - | - | - | 2.0 | 6.8 | 13.0 | 19.5 |
| R&D | 9.6 | 30.2 | 44.5 | 50.0 | 75.0 | 60.0 | 65.0 | 70.0 |
| SG&A | 4.2 | 7.0 | 10.0 | 29.0 | 40.0 | 50.0 | 60.0 | 75.0 |
| Other | - | - | - | - | - | - | - | - |
| Operating Expenses | 13.8 | 37.3 | 54.5 | 79.0 | 117.0 | 116.8 | 138.0 | 164.5 |
| Operating Income / (Loss) | (13.8) | (37.3) | (54.5) | (79.0) | (92.0) | (21.8) | 62.0 | 160.5 |
| Interest Income | - | 0.1 | 0.4 | 0.3 | 0.8 | 0.8 | 0.4 | 0.9 |
| Interest Expenses | - | (0.7) | (1.6) | (0.8) | (0.4) | - | - | - |
| Foreign Currency Transaction Gains (Losses), net | (0.2) | (0.0) | - | - | - | - | - | - |
| Pretax net income | (14.0) | (37.9) | (55.7) | (79.5) | (91.6) | (21.0) | 62.4 | 161.4 |
| Accretion of redeemable convertible preferred stoc | (0.2) | - | - | - | - | - | - | - |
| Taxes | - | - | - | - | - | - | - | - |
| <i>Tax Rate</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> | <i>0%</i> |
| GAAP Net Income | (14.2) | (37.9) | (55.7) | (79.5) | (91.6) | (21.0) | 62.4 | 161.4 |
| GAAP EPS | \$ (3.11) | \$ (2.89) | \$ (2.40) | \$ (2.75) | \$ (3.10) | \$ (0.70) | \$ 2.05 | \$ 5.20 |
| Diluted Shares Outstanding (MM) | 4.6 | 13.1 | 23.2 | 28.9 | 29.5 | 29.8 | 30.4 | 31.0 |

Source: Cowen and Company

Valuation Methodology And Risks

Valuation Methodology

Biotechnology:

In calculating our 12-month target price, we employ one or more valuation methodologies, which include a discounted earnings analysis, discounted cash flow analysis, net present value analysis and/or a comparable company analysis. These analyses may or may not require the use of objective measures such as price-to-earnings or price-to-sales multiples as well as subjective measures such as discount rates.

We make investment recommendations on early stage (pre-commercial) biotechnology companies based upon an assessment of their technology, the probability of pipeline success, and the potential market opportunity in the event of success. However, because these companies lack traditional financial metrics, we do not believe there are any good methodologies for assigning a specific target price to such stocks.

Investment Risks

Biotechnology:

There are multiple risks that are inherent with an investment in the biotechnology sector. Beyond systemic risk, there is also clinical, regulatory, and commercial risk. Additionally, biotechnology companies require significant amounts of capital in order to develop their clinical programs. The capital-raising environment is always changing and there is risk that necessary capital to complete development may not be readily available.

Risks To The Price Target

Zafgen is developing candidates for the treatment of orphan disorders, obesity, and metabolic conditions. The majority of Zafgen's market capitalization is dependent upon the success of lead candidate beloranib. Beloranib's value could be adversely impacted should its clinical trials fail, should the regulatory agencies deny approval, or should its commercial opportunity not materialize as we project. In fact, all of Zafgen's drug candidates face clinical and regulatory risk. With the future development path depending on the evolution of clinical data, future revenue forecasts are uncertain. The commercial outlook for Zafgen's candidates could additionally be altered by safety/efficacy findings, emerging competition, alterations in the medical treatment paradigm, or changes in the pricing environment. Some of Zafgen's projected market exclusivity depends on patents, which are subject to challenge by generic drugmakers.

Addendum

Stocks Mentioned In Important Disclosures

| Ticker | Company Name |
|--------|-------------------------|
| BMRN | BioMarin Pharmaceutical |
| GILD | Gilead Sciences |
| NBIX | Neurocrine Biosciences |
| ZFGN | Zafgen |

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

Cowen and Company, LLC and/or its affiliates make a market in the stock of Zafgen, BioMarin Pharmaceutical, Gilead Sciences and Neurocrine Biosciences securities.

Zafgen and Neurocrine Biosciences have been client(s) of Cowen and Company, LLC in the past 12 months.

Zafgen and Neurocrine Biosciences is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from Zafgen and Neurocrine Biosciences.

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of Zafgen and Neurocrine Biosciences within the past twelve months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, <https://cowenlibrary.bluematrix.com/client/library.jsp>.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at <https://cowen.bluematrix.com/sellside/Disclosures.action>.

Price Targets: Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Copyright, User Agreement and other general information related to this report

© 2014 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York (646) 562-1000 **Boston** (617) 946-3700 **San Francisco** (415) 646-7200 **Chicago** (312) 577-2240 **Cleveland** (440) 331-3531 **Atlanta** (866) 544-7009 **London** (affiliate) 44-207-071-7500

COWEN AND COMPANY RATING DEFINITIONS

Cowen and Company Rating System effective May 25, 2013

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Rating System until May 25, 2013

Outperform (1): Stock expected to outperform the S&P 500

Neutral (2): Stock expected to perform in line with the S&P 500

Underperform (3): Stock expected to underperform the S&P 500

Assumptions: Time horizon is 12 months; S&P 500 is flat over forecast period

Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

Buy – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

Sell – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

Hold – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

Cowen And Company Rating Definitions

Distribution of Ratings/Investment Banking Services (IB) as of 09/30/14

| Rating | Count | Ratings Distribution | Count | IB Services/Past 12 Months |
|----------|-------|----------------------|-------|----------------------------|
| Buy (a) | 440 | 59.95% | 105 | 23.86% |
| Hold (b) | 278 | 37.87% | 10 | 3.60% |
| Sell (c) | 16 | 2.18% | 0 | 0.00% |

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.

Zafgen Rating History as of 11/11/2014

powered by: BlueMatrix



BioMarin Pharmaceutical Rating History as of 11/11/2014

powered by: BlueMatrix



Gilead Sciences Rating History as of 11/11/2014

powered by: BlueMatrix



Neurocrine Biosciences Rating History as of 11/11/2014

powered by: BlueMatrix



Legend for Price Chart:

I = Initiation | 1 = Outperform | 2 = Market Perform | 3 = Underperform | UR = Price Target Under Review | T = Terminated Coverage | \$xx = Price Target | NA = Not Available | S=Suspended

Points Of Contact

Analyst Profiles



Phil Nadeau, Ph.D.

New York

646.562.1336

phil.nadeau@cowen.com

Phil Nadeau is a senior analyst covering biotech. He has been at Cowen for 12 years. Phil holds an SB/M.Eng from MIT, and a Ph.D. from Harvard.

Reaching Cowen

Main U.S. Locations

New York

599 Lexington Avenue
New York, NY 10022
646.562.1000
800.221.5616

Atlanta

3399 Peachtree Road NE
Suite 417
Atlanta, GA 30326
866.544.7009

Boston

Two International Place
Boston, MA 02110
617.946.3700
800.343.7068

Chicago

181 West Madison Street
Suite 1925
Chicago, IL 60602
312.577.2240

Cleveland

20006 Detroit Road
Suite 100
Rocky River, OH 44116
440.331.3531

San Francisco

555 California Street, 5th Floor
San Francisco, CA 94104
415.646.7200
800.858.9316

International Locations

Cowen International Limited

London

1 Snowden Street - 11th Floor
London EC2A 2DQ
United Kingdom
44.20.7071.7500


Cowen and Company (Asia) Limited

Hong Kong

Suite 1401 Henley Building
No. 5 Queens Road Central
Central, Hong Kong
852 3752 2333



 @CowenResearch

 Cowen and Company